Collaborative Research Database

The CBTDDC is committed to strengthening collaborations between an international, multi-disciplinary network of clinicians and researchers whose combined expertise will accelerate the development of drug delivery systems that target brain diseases.

With this in mind, we are developing this Collaborative Research Database. We believe that this database will offer unrivalled opportunities for open dialogue, sharing of resources and collaborative research. But its success will depend on the number of researchers who submit their details for inclusion. We strongly encourage you to help make this a powerful research tool by submitting your details for inclusion. Thank you.

 

Alexander-Cameron

Alexander, Cameron

Professor of Polymer Therapeutics University of Nottingham, UK School of Pharmacy I lead the Division of Molecular Therapeutics and Formulation at the School of Pharmacy in Nottingham. The main areas of research within Polymer Therapeutics are the synthesis and characterisation of bioresponsive materials and externally-activated biosensing and release polymers. These polymers can be triggered to release signals or therapeutic cargoes by heat, light, pH, redox and enzymatic activity. Bioresponsive polymers drug delivery biomaterials synthesis

Al-Jamal-Khuloud

Al-Jamal, Khuloud

King's College, London, UK Drug Delivery & Nanomedicine I am the chair of Drug Delivery & Nanomedicine in the School of Cancer and Pharmaceutical Sciences at King's College London. I lead a research team focusing on the design and development of novel nanoscale delivery systems specifically for drug, gene, vaccine and radionuclide delivery for therapeutic or diagnostic applications, particularly in the field of cancer studies and brain drug delivery. nanoscale delivery systems nanotubes

Battaglia-Giuseppe

Battaglia, Giuseppe

Chair of Molecular Bionics University College London, UK Nanomedicine, Cancer targeting, and BBB biophysics I am the Chair of Molecular Bionics and Honorary Professor of Chemical Engineering in the Department of Chemistry at the University College London. Several of our activities involve the design of novel carriers to target cancer cells and/or cross the blood-brain barrier. We have developed a workflow of activities that allows the design of super-selective nanocarriers, their study in complex in vitro models and finally the pre-clinical validation in relevant models. Nanomedicine polymersomes blood brain barrier (BBB) cancer targeting

Bienemann-Alison

Bienemann, Alison

Research Fellow University of Bristol, UK Functional Neurosurgery I am currently working as a research fellow for Professor Steven Gill, Functional Neurosurgery research group. My main area of expertise is in the progression of translational research towards the clinical setting, utilising both small and large animals models. CED convection enhanced delivery

Boyd-Marie

Boyd, Marie

Reader in Translation Cancer Research Radiobiology University of Strathclyde, UK Twenty years experience in combination therapeutics including translation of clinical schemes in paediatric populations. Extensive experience as PI and CI of multidisciplinary scientific and training grants in the cancer field. Experience with brain tumour 2D and 3D models and interrogation of chemo- and radio-therapeutics in vivo. Extensive clinical and industrial network in the brain tumour arena. 2D models 3D models chemotherapeutics radiotherapeutics

Bradshaw-Tracey

Bradshaw, Tracey

University of Nottingham, UK Biomedical Sciences More than 25 years' experience in the cancer pharmacology and drug discovery fields investigating antitumour activity and mechanisms of action of NCEs, natural products and novel formulations of test agents to enhance and target drug delivery. Of particular interest are self-assembling small molecule hydrogelators and apoferritin-encapsulated formulations for treatment of intractable, drug-resistant cancers. Pharmacology hydrogelators apoferritin-encapsulated formulations

Braz-de-Sousa-Ana-Leticia

Braz de Souza, Ana Leticia

University of Nottingham, UK Pharmacy I am working on the development of micro and nanoparticles for brain cancer therapy. microparticles nanoparticles

Brem-Henry

Brem, Henry

Professor of Neurosurgery, Ophthalmology, Oncology and Biomedical Engineering Johns Hopkins University, USA I have led a neurosurgical brain tumor research team since 1984, and have extensive PI/CI experience on brain tumor and neuro-oncology grants. My team invented and developed Gliadel® wafers to intraoperatively deliver chemotherapy to brain tumors. This work has been expanded to include local delivery of anti-angiogenic therapies, chemotherapeutic agents and resistance modifiers for primary and metastatic brain tumors. I have worked with collaborators to develop and synthesize new classes of polymers and microchips for drug delivery. Tumor type: rodent brain tumor cell lines, established human glioma lines, primary cell lines derived from patient samples. immunotherapy Gliadel intraoperative chemotherapy microchips polymers rodent brain tumour cell lines established human glioma lines primary cell lines localised drug delivery

Brennan-Paul

Brennan, Paul

Senior Clinical Lecturer and Honorary Consultant Neurosurgeon University of Edinburgh, UK Surgical Neuro-Oncology As a neurosurgeon specialising in surgical neuro-oncology I have direct experience with carmustine wafers in the treatment of high grade glioma. My clinical work informs my interest in developing novel strategies for delivering chemotherapy focally in management of brain tumours. This led to the collaborations with Dr Unciti-Broceta developing a palladium activated prodrug. I also collaborate with the IMPACT (https://www.impact.eng.ed.ac.uk) team who are developing implantable microsystems for personalised anti-cancer therapy, which complements my interest in localised drug delivery. carmustine wafers palladium Impact

Choi-James

Choi, James

Imperial College, London, UK Department of Bioengineering Noninvasive and localised drug delivery across the blood-brain barrier using ultrasound and microbubbles. I have over 12 journal publications on this topic and continue to develop different aspects of this technology. ultrasound microbubbles

Cima-Michael

Cima, Michael

Professor of Engineering Massachusetts Institute of Technology, USA Koch Institute of Integrative Cancer Research Lead a research lab focusing on developing medical devices for single compartment drug delivery with a history of clinical translation. Currently developing a minimally invasive device for chronic fluid infusion and electrical interfacing with discrete deep-brain structures. Experience as a founder of four startup companies and consulting for several pharmaceutical companies. Medical Devices micropump localized drug delivery neural implant

Cohen-Kenneth

Cohen, Kenneth

Professor (Oncology and Pediatrics) Johns Hopkins University, USA Experienced clinical trialist with a particular focus on small scale clinical trial design. Previous and ongoing research related to local drug delivery including the original development of Gliadel® in children and intra-arterial chemotherapy for children with DIPG. Tumor type: All pediatric brain tumors. clinical trial design Gliadel intra-arterial

De-Vleeschouwer-Steven

De Vleeschouwer, Steven

Staff neurosurgeon / Professor University Hospitals Leuven, KU Leuven, Belgium Experimental neurosurgery and neuroanatomy Preclinical and conceptual research in nose-to-brain delivery of innovative therapeutics including formulated RNAi substances. Preclinical research in consortium for development of multichannel microcatheter for CED in brain tumors including brainstem locations. nose-to-brain transport tumor micro-environment RNAi CED convection-enhanced delivery intra-nasal intranasal

Evans-Stephen

Evans, Stephen

University of Leeds, UK Expertise in:1. Developing Therapeutic Microbubbles, as theranostic agents, for enhanced, targeted drug delivery to cancers.2. Nanobubble loaded Liposomes for Drug Delivery microbubbles theranostic agents nanobubbles liposomes

Farrer-Nicola

Farrer, Nicola

Synthetic and Analytical Chemist University of Oxford, UK I am primarily a synthetic and analytical chemist with a background in Natural Sciences (Physics, Biochemistry, Chemistry). My multi-disciplinary research involves the development of metal-based systems that respond to external stimuli (light, ultrasound) for application in the imaging and treatment of cancer. During postdoctoral work I developed photo-activatable anti-cancer platinum prodrugs. As a Wellcome Trust Career Re-Entry Fellow I am currently developing novel multimodal anti-cancer complexes and investigating their encapsulation and delivery using ultrasound. synthetic chemistry Analytical Chemistry metal-based systems drug encapsulation ultrasound

Green-Adam

Green, Adam

Assistant Professor of Pediatrics Children's Hospital, Colorado, USA Pediatric high-grade glioma One of my areas of investigation is systemic chemotherapy penetration to pediatric glioblastoma and DIPG in patient-derived xenograft models and clinical trials. chemotherapy penetration glioblastomas DIPG model

Green-Jordan-J

Green, Jordan J

Associate Professor of Biomedical Engineering, Neurosurgery, Oncology, Ophthalmology, Materials Science & Engineering, and Chemical & Biomolecular Engineering Johns Hopkins University, USA My previous and ongoing research focuses on drug, gene and cellular therapies to treat brain tumors. At Johns Hopkins University School of Medicine, I direct the Biomaterials and Drug Delivery Laboratory, serve on the executive committee of the Institute for NanoBioTechnology, and am associate director of the Translational Tissue Engineering Center. I am also Vice Chair of the Drug Delivery Special Interest Group of the Society For Biomaterials. My areas of expertise are: drug delivery systems, biomaterials, nanotechnology, non-viral gene therapy, immunotherapy and cell therapy. Tumor type: All pediatric brain tumors. biomaterials nanotechnology non-viral gene therapy cell therapy immunotherapy stem cells

Grundy-Richard

Grundy, Richard

Professor of Neuro-Oncology and Cancer Biology / Co-Director CBTRC University of Nottingham, UK Children's Brain Tumour Research Centre (CBTRC) My expertise lies in molecular neuro-oncology, functional imaging, biomarkers, localised drug delivery systems and clinical trials. In particular, I have significant expertise in intraventricular chemotherapy predominantly using etoposide. I am also chief UK investigator for the SIOP ependymoma II trial. Tumour type: Ependymoma, High Grade Glioma, Medulloblastoma. functional imaging biomarkers clinical trials polymers high grade glioma HGG medulloblastoma localised delivery Ependymoma

Hales-Patrick

Hales, Patrick

Children with Cancer UK Research Fellow University College London, UK My research area covers advanced MRI techniques for improved diagnosis and monitoring of treatment response in paediatric cancer. I specialize in the development of new imaging techniques for measuring the cellular and vascular structure of paediatric brain tumours. I am currently leading the integration of these techniques into clinical practice at Great Ormond Street Children's Hospital. Using these techniques, we can monitor the blood supply to a tumour, which will have a strong influence on the efficacy of drug delivery. Changes in the tumour microstructure as a response to treatment can also be measured. Magnetic Resonance Imaging diffusion-weighted imaging perfusion-weighted imaging paediatric cancer MRI

Hargrave-Darren

Hargrave, Darren

Reader in Paediatric Neuro-Oncology and Consultant Paediatric Neuro-Oncologist University College London, Institute of Child Health / Great Ormond Street Hospital, UK I have expertise in drug development and am an experienced chief investigator in early and late phase clinic trials. I have strong links with pharmaceutical partners and am Chair of the UK Novel Agents subgroup. My collaborations with UCL/GOSH colleagues in drug delivery include: novel nanotechnology- polymersomes, intra-arterial chemotherapy delivery (retinoblastoma) and interest in CED. Tumour type: all paediatric brain tumours. clinical trials nanotechnology polymers intra-arterial delivery convection-enhanced delivery CED

Howarth-Alison

Howarth, Alison

3rd year PhD student University of Portsmouth, UK I am a 3rd year PhD student, studying novel and repurposed therapeutics for the treatment of paediatric high grade glioma. I have carried out a genome wide CRISPR-Cas9 screen to determine essential survival genes, and with an additional low dose antidepressant, we aim to identify novel sensitivities for therapeutic effect. Previously, I have worked as team leader in the primary pharmacology group (Pfizer, UK) and more recently in the target discovery institute (TDI) high throughput screening group (University of Oxford). paediatric high grade glioma HGG repurposing

Itzhaki-Laura

Itzhaki, Laura

Professor University of Cambridge, UK Department of Pharmacology My group is developing a new class of protein drugs to intracellular targets for the treatment of cancers (including brain cancers) and neurodegenerative diseases, and hence we need to find methods to deliver these proteins to the brain and into cells. protein drugs

Jackson-Sadhana

Jackson, Sadhana

Assistant Clinical Investigator National Institutes of Health, USA Neuro-oncology I have experience with the use of brain microdialysis, pharmacokinetic analysis, and utilization of preclinical models to study central nervous system (CNS) pharmacology. I lead collaborative preclinical and clinical studies focused on understanding blood-brain barrier integrity in normal brain and malignant gliomas with an effort to develop novel treatment strategies for patients with brain tumors. brain microdialysis neuropharmacology blood-brain barrier malignant glioma

Janowski-Miroslaw

Janowski, Miroslaw

Associate Professor Johns Hopkins University, USA Expertise in intra-arterial drug delivery using MRI guidance. intra-arterial MRI

Jones-Arwyn

Jones, Arwyn

Professor of Membrane Traffic and Drug Delivery Cardiff University, Wales, UK School of Pharmacy and Pharmaceutical Sciences I have been developing in vitro assays for analysing transcytosis in murine bEnd3 cells and human brain derived microvascular endothelial cells. This is for monitoring delivery and intracellular traffic of ligands, nanoparticles and antibodies. This was achieved using techniques such as live cell imaging, confocal microscopy and flow cytometry. drug delivery nanoparticles endocytosis cancer cell biology public engagement in science

Katsila-Theodora

Katsila, Theodora

Senior Research Scientist University of Patras, Greece My research focus spans pan-omics strategies coupled to information technologies toward better-informed decision-making and genotype-to-phenotype correlations. Sharing both academic and industrial research experience, I have interdisciplinary wet- and dry-lab expertise. 3D omics biomarkers

Killick-Cole-Clare

Killick-Cole, Clare

Post-Doctoral Research Associate University of Bristol, UK Functional Neurosurgery I am a post-doctoral research associate with a background in molecular oncology. I've been working for Professor Steven Gill for the past three years. During this time, my focus has been the preclinical analysis of drugs and drug combinations for administration to brain tumours by intermittent convection-enhanced delivery. CED convection-enhanced delivery

Kortylewski-Marcin

Kortylewski, Marcin

Associate Professor Beckman Research Institute at City of Hope, USA Cancer immunotherapy My group focuses on the development of oligonucleotide-based cancer immunotherapies. We demonstrated the feasibility of using TLR9 agonists, CpG DNA, for targeted delivery of therapeutic STAT3 siRNA or ASO to immune cells infiltrating solid tumors, such as glioma. The first two generations of CpG-STAT3 inhibitors are undergoing safety/tolerability studies assisting IND filing for therapy of human B cell lymphoma and malignant glioma. I am an active member of the Oligonucleotide Therapeutics Society (Advisory Council Member), ASGCT and AACR. oligonucleotide therapeutics Cancer immunotherapy siRNA CpG STAT3 TLR9

Leite-Diana

Leite, Diana

Senior Research Associate University of Portsmouth, UK Brain Tumour Centre I am a Senior Research Associate at the Brain Tumour Centre, University of Portsmouth, focused on the development of a 3D in vitro model of brain tumours. During an MSc in Biomedical Engineering, I explored the use of polymeric nanoparticles as drug carriers to the bone. Later, as a Research Assistant, I worked with a gene delivery system based on dendrimers for brain regeneration. I have recently completed a PhD dedicated to peptide nanomaterials for the treatment of brain tumours. 3D model polymeric nanoparticles gene delivery dendrimers peptide nanomaterials

Maherally-Zaynah

Maherally, Zaynah

Research Fellow University of Portsmouth, UK Pharmacy and Biomedical Sciences My current project involves employing a 3D all human 'in vitro' blood brain barrier (BBB) model, recently developed within our laboratories, to assess a range of 'in house' nanoparticles as efficient carriers to facilitate anti-glioma drug across the BBB. In parallel I am also working on investigating a panel of cell cultures derived from breast and lung cancers as well as melanoma with regard to constitutive expression of a number of genes that may be implicated in metastasis to the brain. MODELS nanoparticles

Marlow-Maria

Marlow, Maria

Pharmacist University of Nottingham, UK School of Pharmacy I am a pharmacist with a PhD in drug delivery and over 18 years' experience in drug delivery in industry. I have worked on many different drug delivery options and formulations including oral, intravenous and inhaled dosage forms. In 2012, I made the transition back to academia and now work on self-assembling molecules for localised drug delivery including intra-tumoural drug delivery, basal cell carcinoma and cancer cell adhesion. pharmacist self-assembling molecules hydrogel nanocomposites

McConville-Chris

McConville, Chris

Senior Lecturer University of Birmingham, UK Pharmaceutics, Drug Formulation and Delivery I am a Senior Lecturer in Pharmaceutics, Drug Formulation and Delivery at the University of Birmingham. I have extensive expertise in the design, development and manufacture of both implantable drug delivery devices and nanoparticles. I also have extensive expertise in the solubility enhancement of poorly soluble drugs. I have been involved in the development of a number of drug delivery devices and formulations that have been evaluated in the clinic, one of which is currently in Phase III clinical testing. pharmaceutics drug formulation implantable drug delivery device nanoparticles

McGuire-Kerry

McGuire, Kerry

Undergraduate Student University of Strathclyde, UK Pharmacy Currently undertaking a dissertation on the use of PD-1 inhibitors in paediatric brain tumours.

Mullen-Alexander

Mullen, Alexander

Professor of Pharmacy Practice University of Strathclyde, UK I am a qualified pharmacist with clinical, industrial and academic experience in drug and delivery device development with an ongoing interest in the treatment of cancers, including those of the central nervous system. My expertise lies in designing injectable/implantable devices that can deliver a variety of drugs and nanoparticles over prolonged periods with a view to minimising the recurrence of cancer from the tumour margins left after standard neurosurgery interventions. These treatments are to synergise with other treatment modalities such as radiotherapy. Tumour type: glioma- and medulloblastoma-derived cell lines. nanoparticles glioma cell lines medulloblastoma cell lines device development polymers formulation Analysis

Needham-David

Needham, David

Honorary Professor University of Nottingham, UK Nanomedicines New endogenous-inspired nanoparticle designs for metastatic cancer, including: synthesis, characterisation, and formulation of the pro-drug Niclosamide Stearate (NSNP); NSNP testing in vitro for cell-uptake and cytotoxicity in glioblastoma, breast and prostate cancers; and in vivo preclinical studies showing encouraging results in flank and metastatic tumours with growth delays and extended lifetimes for the NSNP-treated animals. Also includes PET-imageable nanoparticles which, in combination with the NSNPs, forms a suite of diagnostic and therapeutic "Individualised nano-medicines" for cancer. Nanomedicines cancer prodrugs

Neves-Vera

Neves, Vera

Senior Staff Researcher Lisbon University, Portugal Instituto de Medicina Molecular I have expertise in blood-brain barrier (BBB) models in vitro and biodistribution in vivo, as well as in the design and synthesis of trans-BBB peptide shuttles. I have also conducted research in collaboration with other groups to test the efficacy of these peptides fused to therapeutic proteins, such as antibodies for Alzheimer's disease. blood-brain barrier peptide shuttles drug delivery systems Nanomedicine BBB MODELS

Ong-Zhan-Yuin

Ong, Zhan Yuin

Academic Fellow University of Leeds, UK Health Engineering I am a University Academic Fellow in Health Engineering (Tenure-track), holding a joint appointment between the Schools of Physics and Astronomy and Medicine at the University of Leeds. My research focuses on the design and evaluation of well-defined multifunctional nanomaterials for the targeted delivery of therapeutics in combination with photothermal therapy to address unmet medical needs. nanomaterials photothermal therapy

Pearl-Monica

Pearl, Monica S

Associate Professor of Radiology Johns Hopkins University, USA Division of Interventional Neuroradiology, School of Medicine I have extensive clinical and research expertise with catheter-based intra-arterial therapies for adult and pediatric neurovascular disorders of the brain and spine. My neuroradiology background allows for developing complementary neuroimaging platforms to manipulate the blood brain barrier and better define drug distribution. I am PI for two active clinical trials for IA drug delivery (NCT01293539 and NCT01688401) for retinoblastoma and DIPG. Tumor type: DIPG, Retinoblastoma. DIPG retinoblastoma intra-arterial Imaging

Perez-Garcia-Lluisa

Perez-Garcia, Lluisa

Anne McLaren Research Fellow University of Nottingham, UK Pharmacy My current interests are mainly in the field of nanobiomedicine, and include the use of metallic and inorganic nanoparticles as well as supramolecular hydrogels for drug delivery of anticancer agents, especially photosensitizers for photodynamic therapy. Also, the bio-functionalization of silicon microparticles to study, individually tag and actuate inside living cells (multiplexing materials). I was appointed as an Anne McLaren Research fellow in September 2017. nanobiomedicine nanoparticles hydrogels photosensitizers

Pilkington-Geoff

Pilkington, Geoff

Professor University of Portsmouth, UK Brain Tumour Research Centre Development of state-of-the-art 3D all-human models (2D and 3D, static and dynamic) in vitro models of the blood-brain barrier for use in drug delivery through transient opening mechanism and nanoparticle delivery. Currently working on models for tumour spread (vascular and CSF/leptomeningeal) in medulloblastoma as well as on 3D multicellular (neoplastic and non-neoplastic) models for drug testing in brain tumour. MODELS nanoparticle tumour spread transient opening

Preat-Veronique

Preat, Veronique

Professor Universite Catholique de Louvain, Belgium Advanced Drug Delivery and Biomaterials I lead the group Advanced Drug Delivery and Biomaterials at the University of Louvain. After the definition of an unmet need, a multidisciplinary approach is used to design new drug delivery systems and demonstrate their efficacy and safety in vitro and in vivo. The main area of research is the design, characterisation and preclinical testing of nanomedicines, in particular for glioblastoma treatment. biomaterials Nanomedicine immunotherapy vaccine hydrogel

Rahman-Ruman

Rahman, Ruman

Assistant Professor of Molecular Neuro-Oncology University of Nottingham, UK My research group has developed a localised drug delivery system in which a biodegradable polymer (PLGA/PEG) is applied around the tumour cavity wall at neurosurgical resection. The polymer forms a paste at room temperature, which solidifies next to the surgical cavity wall at body temperature. This gives spatial control over dose delivery, extending the length of time infiltrative tumour cells are exposed to the drug. My expertise covers: (1) local biomaterial-based drug delivery systems for intracranial tumours, (2) 3D brain tumour models for drug screening, (3) bio-instructive nanotherapeutics, (4) HDAC inhibitors, (5) brain intra-tumour heterogeneity. biomaterials polymers localised drug delivery intraoperative chemotherapy 3D models nanotherapeutics HDAC inhibitors intra-tumour heterogeneity.

Rodriguez-y-Baena-Ferdinando

Rodriguez y Baena, Ferdinando

Imperial College, London, UK Mechanical Engineering Since 2016, I have been coordinating a European project on neurosurgical drug delivery for cancer therapy, codenamed EDEN2020 (www.eden2020.eu). This project resulted from a 10-year activity on surgical needle steering, which is currently at the core of the EDEN2020 endeavour. neurosurgical drug delivery EDEN2020 surgical needle steering

Sánchez-Gómez-Pilar

Sánchez-Gómez, Pilar

National Health Institute Carlos III, Spain Neurooncology We are experts in the development of preclinical glioma models, working with patient-derived cells as 3D spheres or xenografts, where test the efficiency of different therapeutic drugs. We have characterized the behaviour of these lines in the mouse brain, from the most invasive ones to the most angiogenic and necrotic tumors. We are also very interested in allogenic and immunocompetent models, to analyse the participation of the tumor microenvironment in the response to chemotherapy (both as a physical barrier and as protective cells). Glioblastoma mouse models preclinical assays EGFR tumor microenvironment

Sandberg-David

Sandberg, David

Principal Investigator Health Science Center and MD Anderson Cancer Center, University of Texas, USA McGovern Medical School For over a decade, I have studied local drug delivery into the fourth ventricle of the brain to treat recurrent, malignant posterior fossa tumors in children. I first studied safety and pharmacokinetics in piglets and then non-human primates. These experiments led to a promising pilot trial in humans, and we currently have several open clinical trials for children with recurrent malignant brain tumors originating in the fourth ventricle. local drug delivery Fourth ventricle

Schatzlein-Andreas

Schatzlein, Andreas

Professor of Translational Therapeutics University College London, UK School of Pharmacy Drug delivery to the brain is one of our key areas of research and we have published extensively in this area. We have developed a polymer based system that increases drug transport either across the BBB or by nose-to-brain administration. For this reason we have been chosen as partner for example for the EU consortium EPITARGET - to deliver epilepsy medication. The system is being commercially developed by Nanomerics. Nanomedicine

Schmainda-Kathleen

Schmainda, Kathleen

Professor Medical College of Wisconsin, USA Radiology Research My team has developed advanced MRI methods to aid in the evaluation of treatment response in patients with brain tumors. While most of our work has been in the adult population, recent work includes pediatric patients. diffusion MRI perfusion MRI

Sirianni-Rachael

Sirianni, Rachael

Professor of Polymer Therapeutics University of Nottingham, UK School of Pharmacy I lead the Division of Molecular Therapeutics and Formulation at the School of Pharmacy in Nottingham. The main areas of research within Polymer Therapeutics are the synthesis and characterisation of bioresponsive materials and externally-activated biosensing and release polymers. These polymers can be triggered to release signals or therapeutic cargoes by heat, light, pH, redox and enzymatic activity. Bioresponsive polymers drug delivery biomaterials synthesis

Stanyard-Ryan

Stanyard, Ryan

Student Keele University, UK Neuroscience/neuropsychology, counselling, psychotherapy, biological psychology Neuroscience student, experience studying pharmacodynamic and pharmacokinetic systems and BBB diffusion elements. Neurology placement - 1 week bespoke tailored programme made by Chair of Medicine of University Hospital of North Midlands.

Vaideanu-Alexandra

Vaideanu, Alexandra

PhD Student University of Cambridge, UK My PhD focuses on engineering a drug delivery system based on gold nanomaterials for the therapy of glioblastoma multiforme. Synergy between chemo and radiotherapy mediated by gold nanoparticles is further exploited by targeting GBM tumors specifically. We employ amphiphilic peptide sequences which target neuropiln-1 highly expressed in our patient derived cell populations and exploit local delivery by direct injection at the tumor site, using novel Laser-Ablation ICP-MS and MALDI-MS imaging to determine nanoparticle distribution in relation to tumor area. gold nanoparticle glioblastoma multiforme targeting

van-Vuurden-Dannis

van Vuurden, Dannis

Paediatric Neuro-Oncologist VU University Medical Center, Amsterdam, The Netherlands I am Chair of the SIOPE DIPG Network and Registry. My expertise lies in preclinical (combinational) drug screens, convection-enhanced delivery and MRI-guided high intensity focal ultrasound (HIFU) in DIPG, BBB-targeted liposomal drug encapsulation, clinical trials in children, and molecular drug imaging (PET imaging of radiolabeled drugs). Tumour type: paediatric high-grade glioma, diffuse midline gliomas / DIPG. preclinical drug screens combinatorial drug screens convection-enhanced delivery MRI-guided high intensity focal ultrasound HIFU DIPG liposomal delivery liposome clinical trials PET imaging high grade glioma HGG CED

Veal-Gareth

Veal, Gareth

Senior Lecturer / Head of Newcastle Cancer Centre Pharmacology Group Newcastle University, UK Newcastle Cancer Centre Pharmacology Group I have expertise in clinical pharmacology, pharmacokinetics and quantification of drug levels in clinical samples (blood, plasma, CSF, tumour material, etc). My research interests lie in the development and validation of assays for the quantification of novel and established anticancer drugs and their metabolites. I am and have been CI on numerous completed and published clinical pharmacology trials. clinical pharmacology pharmacokinetics Ependymoma Assay development pharmacodynamics

Walczak-Piotr

Walczak, Piotr

Associate Professor of Radiology and Radiological Science Johns Hopkins University, USA My expertise lies in molecular and cellular imaging, and regenerative medicine: (1) Monitoring of drug biodistribution using MRI. (2) Use of stem cells to reduce brain damage caused by chemotherapy. (3) Modeling human brain tumors in animals with intact immune systems. Tumor type: DIPG, Medulloblastoma, GBM. MRI drug biodistribution glial stem cells glial progenitors regenerative medicine intra-arterial DIPG medulloblastoma GBM

Walker-David

Walker, David

Paediatric Neuro-Oncologist University of Nottingham, UK Children's Brain Tumour Research Centre (CBTRC) I am a Paediatric Neuro-Oncologist with expertise in clinical trials in children's cancers and in intrathecal therapy. Over the past 2 decades whilst treating children with brain tumours and contributing to the design of clinical trials, I concluded that systemically administered drugs have had relatively little impact, particularly in malignant brain tumours. Whilst treating children with leukaemia the outstanding success has been linked to successfully treating the CNS, using intra-CSF therapy and intensified systemic therapies. This experience of CNS targeting has highlighted the need to explore this further in childhood brain tumours. clinical trials intrathecal delivery intra csf drug delivery Paediatric Neuro-oncology

Wang-Julie-Tzu-Wen

Wang, Julie Tzu-Wen

Senior Research and Teaching Fellow King's College, London, UK Nanomedicine I am currently a senior research and teaching fellow in Nanomedicine in the School of Cancer and Pharmaceutical Sciences at King's College London. The focus of my research is on the pre-clinical translation of nanomedicines for image-guided delivery of drug/gene/radionuclide. Nanomedicine image-guided delivery

Warren-Kathy

Warren, Katherine

Senior Investigator National Cancer Institute, USA Pediatric Neuro-Oncology Section My research focuses on optimizing clinical trial design by pre-clinically evaluating pharmacokinetics and CNS drug delivery in an animal model. This information is used to determine ideal route of drug delivery (systemic, intrathecal, intranasal, convection-enhanced delivery) to achieve biologically effective dosing at the tumor site. Our animal models have chronically indwelling IV and CSF access, facilitating serial assessment of drug exposures in CSF fluid and the blood compartment simultaneously, allowing for multiple sample collection over time for PK studies. This model has been used to determine CSF and extracellular fluid penetration and toxicities of agents in development for patients with CNS tumors. Tumor type: all children's brain tumors; special focus on brainstem glioma. clinical trial design pharmacokinetics pharmacodynamics preclinical evaluation animal model glioma

Watts-Colin

Watts, Colin

Professor University of Birmingham, UK Neurosurgical oncology I lead the newly established Brain Cancer Program at the University of Birmingham. My research aims to improve the treatment and survival of patients with glioma by understanding the molecular genetic heterogeneity of individual tumours and using that data to develop novel molecular and functional stratification suitable for application in clinical trials. My clinical practice specializes in neurosurgical oncology with a particular interest in intrinsic gliomas and cerebral metastases. glioma genetic heterogeneity neurosurgery

Wheelhouse-Richard

Wheelhouse, Richard

Reader in Medicinal Chemistry University of Bradford, UK Institute of Cancer Therapeutics Expertise in temozolomide analogues, and in prodrug design, synthesis, activation kinetics and evaluation. temozolomide analogues prodrug design

Workman-Robert

Workman, Robert

Postdoctoral Research Associate University of Nottingham, UK Pharmacy I am a Postdoctoral Research Associate based in the School of Pharmacy, at the University of Nottingham. My expertise is in the use of phage display coupled with next generation sequencing to identify diagnostic peptides. Currently this is being performed to identify peptides that can selectively target glioblastoma for delivery and internalisation phage display diagnostic peptides targeting peptides